Human disease
mycosis fungoides
Mondo defines it as: “Classical mycosis fungoides is the most common type of mycosis fungoides (MF), a form of cutaneous T-cell lymphoma, and is characterized by slow progression from patches to more infiltrated plaques and eventually to tumors.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1109 | Mycosis fungoides | OMIA's OMIM numbers | 3 | Human disease |
40.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Dexamethasone | None of these genes | Approved |
| Dexamethasone Phosphoric Acid | None of these genes | Approved |
| Mechlorethamine | None of these genes | Approved |
| Methotrexate | None of these genes | Approved |
| Mogamulizumab | None of these genes | Approved |
| Prednisolone | None of these genes | Approved |
| Prednisone | None of these genes | Approved |
| Resminostat | None of these genes | Awaiting approval |
| Bexarotene | None of these genes | Phase 3 |
| Brentuximab Vedotin | None of these genes | Phase 3 |
| Doxycycline Anhydrous | None of these genes | Phase 3 |
| Hypericin | None of these genes | Phase 3 |
| Lenalidomide | None of these genes | Phase 3 |
| Methoxsalen | None of these genes | Phase 3 |
| Naloxone | None of these genes | Phase 3 |
| Vorinostat | None of these genes | Phase 3 |
| Zanolimumab | None of these genes | Phase 3 |
| Acimtamig | None of these genes | Phase 2 |
| Aldesleukin | None of these genes | Phase 2 |
| Alemtuzumab | None of these genes | Phase 2 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Phase 2 |
| Atezolizumab | None of these genes | Phase 2 |
| Cobomarsen | None of these genes | Phase 2 |
| Curcumin | None of these genes | Phase 2 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 2 |
| Cyclosporine | None of these genes | Phase 2 |
| Doxorubicin | None of these genes | Phase 2 |
| Enzastaurin | None of these genes | Phase 2 |
| Etoposide | None of these genes | Phase 2 |
| Fludarabine | None of these genes | Phase 2 |
| Gemcitabine | None of these genes | Phase 2 |
| Interferon Gamma-1b | None of these genes | Phase 2 |
| Lacutamab | None of these genes | Phase 2 |
| Melphalan | None of these genes | Phase 2 |
| Pacritinib | None of these genes | Phase 2 |
| Panobinostat | None of these genes | Phase 2 |
| Pembrolizumab | None of these genes | Phase 2 |
| Resimmune | None of these genes | Phase 2 |
| Ruxolitinib | None of these genes | Phase 2 |
| Sgn-30 | None of these genes | Phase 2 |
| Tavokinogene Telseplasmid | None of these genes | Phase 2 |
| Temozolomide | None of these genes | Phase 2 |
| Tislelizumab | None of these genes | Phase 2 |
| Tretinoin | None of these genes | Phase 2 |
| Vincristine | None of these genes | Phase 2 |
| 6-O-Benzylguanine | None of these genes | Phase 1/2 |
| Agatolimod | None of these genes | Phase 1/2 |
| Carmustine | None of these genes | Phase 1/2 |
| Interleukin-12 Human Recombinant | None of these genes | Phase 1/2 |
| Linperlisib | None of these genes | Phase 1/2 |
| Magrolimab | None of these genes | Phase 1/2 |
| Tucidinostat | None of these genes | Phase 1/2 |
| Ciaftalan | None of these genes | Phase 1 |
| Duvelisib | None of these genes | Phase 1 |
| Fenretinide | None of these genes | Phase 1 |
| Fludarabine Phosphate | None of these genes | Phase 1 |
| Hiltonol | None of these genes | Phase 1 |
| Interleukin 15, Recombinant Non-Glycosylated | None of these genes | Phase 1 |
| Mol-4239 | None of these genes | Phase 1 |
| Mycophenolate Mofetil | None of these genes | Phase 1 |
| Nivolumab | None of these genes | Phase 1 |
| Ontorpacept | None of these genes | Phase 1 |
| Peginterferon Alfa-2a | None of these genes | Phase 1 |
| Pemetrexed | None of these genes | Phase 1 |
| Recombinant Human Interleukin-15 | None of these genes | Phase 1 |
| Romidepsin | None of these genes | Phase 1 |
| Tacrolimus Anhydrous | None of these genes | Phase 1 |
| Tulmimetostat | None of these genes | Phase 1 |
| Venetoclax | None of these genes | Phase 1 |
| Aminolevulinic Acid | None of these genes | Early phase 1 |
| Imiquimod | None of these genes | Early phase 1 |
| Interferon Alfa-2b | None of these genes | Unknown |
| Psoralen | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.